2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 147

Modular Analysis Of In Peripheral Blood Gene Expression In Rheumatoid Arthritis Captures Reproducible Gene Expression Changes In TNF Responders
Abstract Number: 2563

Modulating Myofibroblast Transition Of Human Scleroderma Fibroblasts Through Inhibition Of Rho Guanine Nucleotidase-Regulated Gene Transcription
Abstract Number: 1172

Molecular Characterisation Of The Killer Cell Immunoglobulin-Like Receptor 3DL2 Binding To Aberrant HLA-B27 Heavy Chains In Spondyloarthritis
Abstract Number: 2702

Molecular Pathogenesis and Genetics Of Tartrate-Resistant Acid Phosphatase Deficiency In Systemic Lupus Erythematosus
Abstract Number: 2223

Monitoring Of Active Matrix Metalloproteinase-3 Using
Abstract Number: 576

Monitoring Of Opportunistic Virus Infections In Systemic Lupus Erythematosus
Abstract Number: 1223

Monitoring Osteoporosis Therapy: Can FRAX Help To Assess Success Or Failure In Achieving Treatment Goals?
Abstract Number: 2784

Mononeuritis Multiplex Predicts The Need For Immunosuppressive Or Immunomodulatory Drugs For Eosinophilic Granulomatosis With Polyangiitis, Polyarteritis Nodosa and Microscopic Polyangiitis Patients Without Poor-Prognosis Factors
Abstract Number: 858

Monosodium Urate Crystal Induced Macrophage Inflammation Is Attenuated By Chondroitin Sulfate: Pre-Clinical Model For Gout Prophylaxis?
Abstract Number: 1134

More Evidence For Breaking The ‘law Of valgus’: Imaging Evidence For Higher Prevalence and Volume Of Bone Marrow Lesions In The Medial Patellofemoral Joint
Abstract Number: 1185

More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares
Abstract Number: 2673

Mortality In Clinically Relevant Osteoarthritis and Rheumatoid Arthritis Compared With The General Population
Abstract Number: 2295

Mortality In Early Rheumatoid Arthritis Comparing Lithuania and Finland. A 13-Year Follow Up
Abstract Number: 2059

Mortality In Polymyositis and Dermatomyositis: A Single Centre Study
Abstract Number: 2778

Mortality In United States Veterans With The HLA-B27 Gene

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].